An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer¿s disease

StatusActive
Effective start/end date3/04/1530/04/20

Funding

  • Lundbeck Pharmaceuticals: $32,034.50

Keywords

  • Aging & Alzheimers, Biotechnology & Drug Development